Bottom line
Is KURE a good fund? The bottom line
KURE is an index health care sector ETF from Krane Shares.
It charges 0.65% — about $65 a year on every $10,000 invested, cheaper than 74% of health care sector funds we track.
It returned +24.8% over one year, −11.8% a year over five years (as of Dec 31, 2025, per its prospectus).
With $71.2 million in net assets and 63 holdings, its largest position is BeOne Medicines AG (8.8%) and the top 10 make up 54.1% of the portfolio.
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 54.1% of assets
Updated Nov 19, 2026
What KURE invests in
The KraneShares MSCI All China Health Care Index ETF (the Fund) seeks to provide investment results that, before fees and expenses, track the price and yield performance of a specific foreign equity securities index. The Funds current index is the MSCI China All Shares Health Care 10/40 Index (the Underlying Index).
Under normal circumstances, the Fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its Underlying Index or in instruments that have economic characteristics similar to those in the Underlying Index. The Underlying Index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint (as defined below), which is designed to measure the equity market performance of Chinese companies in the healthcare sector, as classified by the Global Industry Classification Standard. The securities eligible for inclusion in the Underlying Index include all types of publicly issued shares of Chinese issuers, such as A-Shares, B-Shares, H-Shares, P-Chips and Red Chips, which are described below. The issuers included in the Underlying Index may include mid-cap and large-cap companies. To determine the investable…
From the fund's prospectus (filed Jul 31, 2026).
KURE performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| KURE | +24.8% | −11.8% | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What KURE costs
On a $10,000 investment, KURE's 0.65% expense ratio costs about $65 a year. The prospectus estimates $951 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
KURE top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | BeOne Medicines AG | 8.84% |
| 2 | Innovent Biologics, Inc. | 8.80% |
| 3 | Wuxi Biologics (cayman) Inc. | 7.51% |
| 4 | WuXi AppTec Co., Ltd. | 5.79% |
| 5 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 4.59% |
| 6 | Shenzhen Mindray Bio-Medical Electronics Co Ltd | 4.27% |
| 7 | Akeso Inc | 3.72% |
| 8 | Cspc Pharmaceutical Group Limited | 3.68% |
| 9 | Invesco Government & Agency Portfolio | 3.55% |
| 10 | Sino Biopharmaceutical Limited | 3.39% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 54.1% of the fund. See all top 25 holdings and asset mix →